REM-422

A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS

What's the purpose of the trial?

The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML
Trial status

Accepting patients

Phase
Phase 1
Enrollment
100
Last Updated
4 weeks ago

Partner With us to Treat Your Patient's Cancer.

For referring physicians, our dedicated clinician access line can be reached Monday through Friday 8 am to 6pm (Eastern time) by dialing (888) 874-5087.

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • REM-422

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

REM-422 - AML Patients

Accepting patients

REM-422 - MDS Patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.